Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30105% above fair value
$3.99−0.07 (-1.72%)
Close on Nov 13, 2026Market cap $1.40BP/E –Yield –
Nuvation Bio operating margin
Operating margin is operating income as a percentage of revenue.
Nuvation Bio's operating margin for the twelve months ending Sep 30, 2026 was -61.2%. For fiscal 2025 it was -338.7%, against -7527.3% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -338.7% | +7188.6 |
| FY2024 | Dec 31, 2024 | -7527.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -93.9% | +336.2 |
| Q2 FY2026 | Jun 30, 2026 | -161.1% | +1154.7 |
| Q1 FY2026 | Mar 31, 2026 | 4.7% | +1917.9 |
| Q4 FY2025 | Dec 31, 2025 | -81.3% | +863.2 |
| Q3 FY2025 | Sep 30, 2025 | -430.1% | +6186.2 |
| Q2 FY2025 | Jun 30, 2025 | -1315.7% | +31463.7 |
| Q1 FY2025 | Mar 31, 2025 | -1913.2% | – |
| Q4 FY2024 | Dec 31, 2024 | -944.5% | – |
| Q3 FY2024 | Sep 30, 2024 | -6616.4% | – |
| Q2 FY2024 | Jun 30, 2024 | -32779.4% | – |
See a number that looks wrong?